31 July 2018
Visiongain has launched a new pharma report Diabetic Neuropathy Treatment: World Market 2018-2028: Analysis and Forecasts by Disorder (Peripheral, Autonomic, Proximal, Focal), by Treatment (Drugs, Anti-depressants, Anti-convulsant, Radiotherapy, Physiotherapy, Others), by End-User (Hospitals, Clinics, Pharmacy) and Geography, with Profiles of Leading Companies
Diabetic neuropathy is a chronic disorder characterised by nerve damage caused due to prolonged elevated levels of blood glucose. Diabetic neuropathy may be caused by both type 1 and type 2 diabetes. It affects sensory, motor and autonomic nerves of the body. Treatment of diabetic neuropathy depends upon the type of nerve damage.
The lead analyst of the report commented “Increase in the incidence of diabetes is the major factor increasing the size of the diabetic neuropathy treatment market. Rises in obesity, unhealthy diets, consumption of alcohol & smoking and sedentary lifestyles, along with an ageing population are all factors that in combination are anticipated to increase the diabetic neuropathy market. Furthermore, approvals for drugs associated with diabetic neuropathy control by the FDA is anticipated to further escalate the market growth.
However, side effects of diabetic neuropathy drugs and rising cost of drugs is estimated to hinder the market growth. Ongoing, research and development associated with diabetic neuropathy treatment is anticipated to create new opportunities in the forecast period.
Leading companies featured in the report include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Johnson & Johnson, GlaxoSmithKline plc., Lupin Limited, Glenmark Pharmaceuticals Limited, Depomed, Inc., Astellas Pharma Inc., and Pfizer Inc.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
As lockdowns were imposed in all the countries, diagnosis rates went down in majority of countries during the year hitting the drug sales for some period. Although lockdown measures have been eased up in most countries by mid-year 2020, this trend is expected to continue beyond 2020, stock up of medicines by patients is likely to propel the drug sales in majority of the developed economies, which account for majority of rare diseases.
02 March 2021
Product approval is a major milestone facing all key competitors in the respiratory inhalers market. Several strategies were implemented by key market players between 2015 and Jan 2021.
26 February 2021
The global bile duct cancer drug market has been growing considerably owing to the rising incidence and prevalence rate of bile duct cancer patients worldwide, technological advancement in drug development, and healthcare spending.
22 February 2021
The global Big Data Analytics in Healthcare market has been growing considerably owing to the rising technological advancement, growing investment, and cohesive government policies.